- Home
- BBT vs GHRS Comparison
BBT vs GHRS Comparison
Compare BBT & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBT | GHRS |
|---|---|---|
| Founded | 1846 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BBT | GHRS |
|---|---|---|
| Price | $27.32 | $18.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $34.00 | ★ $42.89 |
| AVG Volume (30 Days) | ★ 929.0K | 302.0K |
| Earning Date | 10-21-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $400,000,000.00 | N/A |
| Revenue This Year | $60.20 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $20.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.81 | $12.04 |
| 52 Week High | $32.83 | $31.44 |
Technical Indicators
Market Signals| Indicator | BBT | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 22.01 |
| Support Level | N/A | $13.19 |
| Resistance Level | $29.45 | $22.88 |
| Average True Range (ATR) | 0.49 | 1.13 |
| MACD | 0.07 | -0.29 |
| Stochastic Oscillator | 33.99 | 2.17 |
Price Performance
Historical ComparisonAbout BBT Beacon Financial Corporation
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.